Transcat's (TRNS) "Outperform" Rating Reiterated at Oppenheimer

Transcat (NASDAQ:TRNS - Get Free Report)'s stock had its "outperform" rating reiterated by stock analysts at Oppenheimer in a research note issued to investors on Thursday, Benzinga reports. They presently have a $125.00 price target on the scientific and technical instruments company's stock, up from their previous price target of $120.00. Oppenheimer's target price suggests a potential upside of 18.76% from the company's previous close.

Several other research analysts have also recently weighed in on TRNS. TheStreet upgraded Transcat from a "c+" rating to a "b" rating in a research report on Wednesday, January 31st. HC Wainwright reaffirmed a "buy" rating and set a $124.00 target price on shares of Transcat in a report on Tuesday.

Transcat Stock Performance

Shares of TRNS stock traded up $0.54 during trading hours on Thursday, hitting $105.25. The company's stock had a trading volume of 39,155 shares, compared to its average volume of 37,969. The stock has a market cap of $929.36 million, a PE ratio of 80.96 and a beta of 0.59. Transcat has a 12-month low of $74.89 and a 12-month high of $115.41. The company has a 50 day moving average of $108.59 and a 200 day moving average of $101.91. The company has a current ratio of 3.37, a quick ratio of 2.81 and a debt-to-equity ratio of 0.01.

Transcat (NASDAQ:TRNS - Get Free Report) last posted its quarterly earnings results on Monday, January 29th. The scientific and technical instruments company reported $0.38 EPS for the quarter, beating the consensus estimate of $0.35 by $0.03. The company had revenue of $65.17 million for the quarter, compared to analyst estimates of $63.36 million. Transcat had a net margin of 4.16% and a return on equity of 9.32%. On average, sell-side analysts forecast that Transcat will post 1.33 EPS for the current fiscal year.

Insider Activity at Transcat

In other Transcat news, CEO Lee D. Rudow sold 5,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $111.30, for a total transaction of $556,500.00. Following the transaction, the chief executive officer now owns 108,478 shares in the company, valued at $12,073,601.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Transcat news, CEO Lee D. Rudow sold 5,000 shares of the company's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $111.30, for a total transaction of $556,500.00. Following the completion of the transaction, the chief executive officer now directly owns 108,478 shares in the company, valued at $12,073,601.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Charles P. Hadeed sold 700 shares of Transcat stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $113.00, for a total transaction of $79,100.00. Following the completion of the sale, the director now owns 22,678 shares in the company, valued at approximately $2,562,614. The disclosure for this sale can be found here. Insiders sold a total of 8,073 shares of company stock worth $900,023 in the last 90 days. Corporate insiders own 4.20% of the company's stock.

Institutional Investors Weigh In On Transcat

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Transcat by 13.3% in the third quarter. Vanguard Group Inc. now owns 425,378 shares of the scientific and technical instruments company's stock worth $41,674,000 after acquiring an additional 49,828 shares during the last quarter. Monashee Investment Management LLC acquired a new stake in Transcat during the 3rd quarter worth $588,000. Quadrature Capital Ltd purchased a new stake in shares of Transcat during the third quarter worth $2,847,000. Rice Hall James & Associates LLC raised its position in shares of Transcat by 59.2% in the third quarter. Rice Hall James & Associates LLC now owns 28,781 shares of the scientific and technical instruments company's stock valued at $2,820,000 after buying an additional 10,697 shares during the last quarter. Finally, Conestoga Capital Advisors LLC raised its position in shares of Transcat by 0.6% in the fourth quarter. Conestoga Capital Advisors LLC now owns 762,861 shares of the scientific and technical instruments company's stock valued at $83,404,000 after buying an additional 4,805 shares during the last quarter. 98.34% of the stock is currently owned by institutional investors and hedge funds.

About Transcat

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.